Crinetics Pharmaceuticals Inc

NASDAQ:CRNX  
16.14
+0.24 (+1.51%)
Earnings Announcements

Crinetics Pharmaceuticals Announces 2021 Clinical Plans And Reports Fourth Quarter And Full Year 2020 Financial Results

Published: 03/30/2021 20:31 GMT
Crinetics Pharmaceuticals Inc (CRNX) - Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results.
Crinetics Pharmaceuticals Inc - Qtrly Loss per Share $0.66.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.65

More details on our Analysts Page.